Zydus Lifesciences announced strong financial results for the third quarter of FY26, ending December 31, 2025. Consolidated revenues grew 30.3% YoY to Rs. 68,645 million. EBITDA rose 30.9% YoY to Rs. 18,164 million, yielding a margin of 26.5%. The impressive performance was significantly boosted by the 113.4% growth in the Consumer Wellness segment due to the full consolidation of CCL.
Zydus Lifesciences Q3 FY26 & 9M FY26 Performance
Zydus Lifesciences Ltd. has released its unaudited consolidated financial results for the quarter and nine months ended December 31, 2025. The company highlighted robust growth across its core businesses, signaling a strong foundation for sustained value creation.
Q3 FY26 Financial Highlights (vs. Q3 FY25)
- Revenue from operations reached Rs. 68,645 million, marking an increase of 30% over last year.
- EBITDA stood at Rs. 18,164 million, growing 31% YoY.
- EBITDA margin improved to 26.5% (an improvement of 20 bps YoY).
- Adjusted Net Profit grew by 9% YoY to Rs. 11,109 million.
- R&D investments for the quarter were Rs. 6,074 million (8.8% of revenues).
9M FY26 Financial Highlights (vs. 9M FY25)
- Revenue from operations was Rs. 1,95,614 million, up 17% YoY.
- EBITDA grew 20% YoY to Rs. 59,207 million, with the margin improving to 30.3% (an 80 bps YoY improvement).
- Adjusted Net Profit increased by 15% YoY to Rs. 38,640 million.
Consolidated Financial Results Summary
The consolidated results show significant year-over-year momentum in Q3 FY26 compared to Q3 FY25:
| Metric | Q3 FY26 (Rs. mn) | Q3 FY25 (Rs. mn) | % Gr. YoY |
|---|---|---|---|
| Revenue from Operations | 68,645 | 52,691 | 30.3% |
| EBITDA | 18,164 | 13,876 | 30.9% |
| EBITDA margin (%) | 26.5% | 26.3% | — |
| Net Profit * | 11,109 | 10,235 | 8.5% |
For the nine months (9M FY26), consolidated revenue reached Rs. 1,95,614 million (up 17.0% YoY), and Net Profit was Rs. 38,640 million (up 15.2% YoY).
Business Segment Performance
The Pharma Business constituted 81% of the Q3 FY26 mix, while Consumer Wellness made up 14% of revenues.
Q3 FY26 Business-wise Revenue Highlights
- Consumer Wellness: Revenue surged by 113.4% YoY to Rs. 9,578 million, driven by the full consolidation of the Comfort Click Limited (CCL) business.
- Pharma Business: Revenues grew 18.2% YoY to Rs. 55,230 million.
- North America Formulations: Posted revenues of Rs. 28,043 million, growing 16.4% YoY.
- India Formulations: Revenues were Rs. 17,094 million, up 12.9% YoY.
- MedTech: Experienced explosive growth (95.6% QoQ) with revenues reaching Rs. 2,996 million, marking the first full quarter of Amplitude Surgical consolidation.
Pharma Business Deep Dive
India Formulations
Registered revenues of Rs. 17,094 million (up 13% YoY). Growth was led by the branded business (14% YoY) and consistent growth in the chronic segment, which now accounts for 45.3% of the portfolio. The company also expanded its precision oncology ecosystem through a strategic collaboration with Myriad Genetics.
North America Formulations
Revenues hit Rs. 28,043 million (up 16% YoY). The US specialty portfolio was strengthened with the launch of Beizray, the first oncology 505(b)(2) product. Furthermore, Zycubo® (copper histidinate) received USFDA approval in January 2026 for treating Menkes disease.
International Markets (IM) Formulations
This segment grew significantly by 38% YoY, achieving revenues of Rs. 7,881 million, driven by strong performance in emerging markets and Europe.
Operational and Innovation Updates
Operations and Compliance
The Jarod injectable facility and the Oral Solid Dosage (OSD) facility in Ahmedabad both received Establishment Inspection Reports (EIRs) with VAI and NAI status, respectively, from the USFDA following recent inspections.
Innovation Pipeline
- NCE Research: Preparing to file the New Drug Application (NDA) for Saroglitazar Magnesium with the USFDA during the current quarter.
- Biotech R&D: Received approval to begin Phase III clinical trials for a second biosimilar antibody drug conjugate in India.
- Vaccines R&D: Initiated a Phase II trial for the Bivalent Typhoid Conjugate Vaccine and secured major tenders with PAHO for rabies vaccines and UNICEF for typhoid conjugate vaccines.
- US Specialty/505(b)(2): Entered an agreement for a novel sterile injectable oncology supportive care product, with expected NDA filing in 2026. The company also entered the US biosimilars space via an in-licensing deal for the biosimilar of Pembrolizumab.
- MedTech: Acquired commercial rights for Nufymco®, an interchangeable biosimilar to Ranibizumab, whose BLA was approved by the USFDA. The proprietary ‘Andy’ robotic surgical system received CE mark approval.
Management Commentary
Dr. Sharvil Patel, Managing Director, stated that the robust performance in 3QFY26 reinforces the strength of the base business. The company remains focused on disciplined M&A, patient centricity, and driving long-term shareholder value.
Earnings Call Information
The post-results earnings call is scheduled for 10:30 a.m. IST on February 10, 2026. Details for joining the call via Zoom are provided for interested participants.
Source: BSE
